...
首页> 外文期刊>New Microbes and New Infections >Development of a novel platform of virus-like particle (VLP) based vaccine against coronavirus 2019 (SARS-CoV-2) by exposing of epitopes: an immunoinformatics approach
【24h】

Development of a novel platform of virus-like particle (VLP) based vaccine against coronavirus 2019 (SARS-CoV-2) by exposing of epitopes: an immunoinformatics approach

机译:通过曝光表位(SARS-COV-2)对基于病毒样粒子(VLP)疫苗的新平台:免疫信息方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The emergence of a rapidly spreading and highly infectious COVID-19 outbreak by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has caused a global pandemic with unprecedented, social and economic dimensions. Therefore, the development of effective strategies is urgent to control COVID-19 outbreak. According to the recent investigations, cell entry of coronaviruses relies on binding of the viral spike glycoprotein to the host cellular receptors. Therefore, in the present study aimed to predict immunogenic epitopes in silico by analyzed spike protein. In parallel, by screening the immunogenic SARS-CoV-2 spike derived epitopes provided in the literature, we chose a set of epitopes believed to induce immunogenic response. Next, we provided the selected epitopes from both approaches, we performed immunoinformatic analysis that map identically to antigen regions and have antigenic properties. Finally, by suggesting a screened set of epitopes, we designed a novel virus-like particle (VLP) vaccine, optimized to be produced in plants by using molecular farming biotechnology techniques. We anticipate our assay to be a starting point for guiding experimental efforts toward the development of a vaccine against SARS-CoV-2.
机译:新型冠状病毒,严重急性呼吸综合征冠状病毒2(SARS-COV-2)的迅速传播和高度传染性Covid-19爆发的出现造成了全球性,具有前所未有的,社会和经济方面的全球大流行。因此,有效策略的发展是迫切控制Covid-19爆发。根据最近的研究,冠状病毒的细胞进入依赖于病毒穗糖蛋白与宿主细胞受体的结合。因此,在本研究中,旨在通过分析的穗蛋白预测硅中的免疫原性表位。并行,通过筛选文献中提供的免疫原性SARS-COV-2尖峰衍生的表位,我们选择了一组被认为的表位诱导免疫原性反应。接下来,我们提供了两种方法的所选表位,我们进行了免疫信息分析,其与抗原区域相同并具有抗原性能。最后,通过建议筛选的表位,我们设计了一种新的病毒样颗粒(VLP)疫苗,通过使用分子耕作生物技术技术在植物中进行优化。我们预计我们的检验是指出针对SARS-COV-2疫苗的实验努力的起点。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号